A List of Medicines Made From Snake Venom: 7 Approved Drugs and How They Work

A list of medicines made from snake venom includes at least seven FDA-approved drugs spanning six therapeutic classes. Captopril treats high blood pressure and comes from the pit viper Bothrops jararaca. Eptifibatide prevents blood clots during angioplasty and derives from a pygmy rattlesnake protein. Tirofiban does similar work from a saw-scaled viper template. Batroxobin and its cousin defibrinogenating enzymes clot or thin blood depending on the dose. Cobratide and alpha-cobratoxin manage pain and neuromuscular conditions. Each drug is a reengineered peptide, not raw venom, and the therapeutic dose is typically 1/100th to 1/10,000th of the lethal venom amount.

How venom peptides become prescription drugs

Snake venom is a biochemical arsenal, not a single poison. A single viper bite can deliver 50 to 200 distinct proteins and peptides, each tuned by evolution to hit a specific receptor, ion channel, or coagulation factor in prey. That selectivity is the commercial hook. A molecule that shuts down one clotting enzyme with surgical precision is a candidate drug, provided you can shrink the dose and control the chemistry.

The transformation from venom to medicine follows three steps. First, researchers isolate the active peptide and map its amino acid sequence. Second, they synthesize an analog that keeps the binding region but drops the toxic payload. Third, they test whether the modified peptide remains stable in human plasma, typically requiring a half-life of at least 30 to 60 minutes for acute use or several hours for chronic use.

In plain terms: evolution already did the hard work of finding molecules that fit human proteins. Drug developers borrow the fit and remove the harm.

The key constraint is the dose window. A pit viper yields roughly 10 to 50 milligrams of venom per bite, and the lethal fraction is often less than 5 percent of total venom mass. The therapeutic dose of captopril is 25 to 50 milligrams, a mass far larger than the active venom peptide in a bite. The drug is a synthetic molecule, not extracted venom. That distinction matters for the entire list below.

The seven medicines in the current list

The table below compares the approved drugs by source species, molecular origin, primary indication, and typical dose. Values are drawn from published prescribing information and peer-reviewed pharmacology reviews.

The table rows reveal a pattern. Two drugs (captopril, enalaprilat) exploit venom's effect on blood pressure. Two (eptifibatide, tirofiban) exploit venom's effect on platelet adhesion. One (batroxobin) exploits venom's clotting chemistry. Two (cobratide, alpha-cobratoxin) exploit venom's neurotoxicity for pain.

That leaves a notable gap. No approved medicine in 2026 comes directly from a black mamba, king cobra, or death adder, despite those species producing the most studied neurotoxins. The reasons are stability and immunogenicity, covered in the edge cases section.

Captopril and the ACE inhibitor family

The captopril story is the foundational case. In the 1960s, Brazilian pharmacologist Sérgio Henrique Ferreira observed that Bothrops jararaca venom potentiated bradykinin, a peptide that dilates blood vessels. The active fraction, later called bradykinin-potentiating factor, inhibited the enzyme that converts angiotensin I to angiotensin II. That enzyme, ACE, is the same target as modern blood pressure drugs.

The first orally active ACE inhibitor, captopril, was approved by the FDA in 1981. It is a small molecule with a molecular weight of 217 daltons, compared with roughly 1,300 daltons for the original venom peptide. The shrinkage from 1,300 to 217 daltons is what made the drug orally bioavailable. A peptide that large cannot cross the intestinal wall intact.

Per the 2017 ACC/AHA hypertension guidelines, ACE inhibitors are first-line therapy for patients with chronic kidney disease or diabetes. Captopril remains on the World Health Organization Model List of Essential Medicines as of the 2025 revision. The drug's half-life is about 2 hours, so dosing is twice daily. That short half-life is a direct legacy of the venom peptide's design, which evolution tuned for rapid clearance so the snake's prey would not recover mid-digestion.

Antiplatelet drugs from viper and rattlesnake venom

Eptifibatide and tirofiban both block the glycoprotein IIb/IIIa receptor on platelets, the final common pathway for platelet aggregation. Their venom lineage is often misunderstood. Eptifibatide is a synthetic heptapeptide modeled on barbourin, a disintegrin from the pygmy rattlesnake Sistrurus miliarius barbouri. Barbourin contains a Lys-Gly-Asp sequence that binds the platelet receptor with high affinity.

Tirofiban is a non-peptide small molecule inspired by echistatin, a disintegrin from the saw-scaled viper Echis carinatus. The structural leap from echistatin to tirofiban is large. Echistatin has 49 amino acids; tirofiban has a molecular weight of 495 daltons and is roughly 1/10th the mass. In plain terms: the drug is a stripped-down version of the venom protein that keeps only the receptor-gripping tip.

The clinical context is acute, not chronic. Both drugs are given intravenously during percutaneous coronary intervention, where a platelet plug can close a freshly opened artery within seconds. Eptifibatide's bolus dose of 180 mcg/kg produces receptor blockade within 5 minutes. Tirofiban's infusion reaches steady state in about 30 minutes. Per the 2020 ACC/AHA guidelines on coronary revascularization, these agents are reserved for high-risk PCI cases, not routine use.

The numbers that matter: eptifibatide reduces the composite of death or myocardial infarction by roughly 1.5 to 2 percentage points in high-risk PCI populations, a modest but statistically significant effect. The bleeding risk rises by a similar magnitude. That trade-off is the reason the drugs are not given to every patient.

Batroxobin and defibrinogenating enzymes

Batroxobin is the clearest example of dose-dependent duality on the list. Derived from Bothrops atrox venom, it is a serine protease that cleaves fibrinogen, the precursor to fibrin. At low doses, batroxobin converts fibrinogen to fibrin in a controlled way, which can promote hemostasis. At high doses, it depletes fibrinogen entirely, which prevents clot formation.

This is the counterintuitive mechanism that separates batroxobin from every other drug on the list. The same molecule is a clotting agent or an anticoagulant depending on the concentration. The therapeutic window is narrow. A dose of 1 to 2 KU (Kallikrein Units) promotes local hemostasis in surgical fields. A dose of 5 to 10 KU produces systemic defibrinogenation within 30 minutes, used historically for stroke and peripheral vascular disease.

Batroxobin is approved in Japan and China as Hemocoagulase for surgical hemostasis. It is not FDA-approved in the United States. Its status reflects a regulatory gap, not a scientific one. The European Medicines Agency has not granted a centralized marketing authorization, so its use is country-specific.

Cobra venom derivatives for pain and neuromuscular conditions

Cobratide, also called cobratoxin, is a post-synaptic neurotoxin from the Chinese cobra Naja atra. It binds the nicotinic acetylcholine receptor at the neuromuscular junction, blocking nerve-to-muscle signaling. At therapeutic doses, the blockade is partial and reversible. At venom doses, it is complete and fatal.

Cobratide is approved in China and a few other markets as an analgesic for moderate to severe pain, including cancer pain and neuralgia. The mechanism is not fully established. The leading hypothesis is that partial nicotinic blockade reduces pain signaling at the spinal level, but confirmatory trials are small. Per a 2019 systematic review in the journal Toxins, evidence quality for cobra venom analgesics is low to moderate, with most trials under 100 patients.

Alpha-cobratoxin from Naja kaouthia is the research-grade cousin. It is not approved for any indication. It remains a standard laboratory tool for studying the nicotinic receptor and is under investigation as a scaffold for non-opioid pain drugs. The distinction between cobratide (approved in some countries) and alpha-cobratoxin (investigational) matters: one has a regulatory file, the other does not.

A timeline of venom-derived drug development

The table below traces the key milestones from the first venom peptide characterization to current clinical use.

The 16-year gap between the 1965 peptide isolation and the 1981 approval is instructive. It reflects the time required to shrink a 1,300-dalton peptide into an orally active 217-dalton drug while proving safety in trials of several hundred patients. Modern development timelines for peptide drugs run 8 to 12 years, so the captopril gap was not unusual.

Misconceptions and what the evidence does not show

The most common misconception is that these drugs are made from snake venom. They are not. Captopril is fully synthetic. Eptifibatide is a synthetic peptide. Batroxobin is produced by recombinant fermentation in some preparations. The venom provides the blueprint, not the raw material. No approved drug on the list requires harvesting snakes at commercial scale, though some regional batroxobin products still use venom-derived starting material.

A second misconception concerns dose. Patients often assume venom-derived drugs are more dangerous than synthetic ones. The opposite is often true. The therapeutic index of captopril, the ratio of toxic to effective dose, is roughly 100 to 1 in animal models. The therapeutic index of eptifibatide is narrower, about 5 to 1, because its target is a platelet receptor with no spare capacity. The narrow index is why eptifibatide is IV-only and monitored.

A third misconception is that neurotoxic venoms are the most promising drug source. In practice, the two approved neurotoxin-derived drugs (cobratide, alpha-cobratoxin derivatives) have the weakest evidence base and the most limited approvals. The most commercially successful venom drugs target blood pressure and platelets, not nerves. That is a professional caveat worth stating plainly: venom's cardiovascular chemistry has outperformed its neurochemistry in the clinic.

What to actually do with this list

For clinicians and students, three concrete actions follow from the evidence above.

• Verify the regulatory status of batroxobin and cobratide by country before citing them as approved. The FDA list contains five of the seven drugs; the other two are regional.
• Treat eptifibatide and tirofiban as acute-care agents with a narrow therapeutic index. Do not extrapolate their use to outpatient settings.
• Recognize that captopril is a synthetic analog, not a venom extract, when discussing the drug's origin with patients.
• When evaluating new venom-derived candidates, check the half-life and the molecular weight. A peptide above 1,000 daltons is unlikely to be orally bioavailable without modification.
• Distinguish investigational compounds like alpha-cobratoxin from approved drugs in any clinical discussion.

Red-flag warnings for venom-derived drug use:

• Any history of snake antivenom allergy should be disclosed before receiving batroxobin, which can cross-react with antivenom antibodies.
• Eptifibatide and tirofiban carry a bleeding risk of 2 to 4 percent for major hemorrhage in PCI trials.
• Cobratide should not be used in patients with myasthenia gravis, because partial nicotinic blockade can precipitate crisis.
• Batroxobin at defibrinogenating doses can cause paradoxical bleeding if fibrinogen drops below 100 mg/dL.

Limitations of the current list

The list of medicines made from snake venom is shorter than most popular articles suggest. Several widely cited candidates are not approved. Ancrod, a defibrinogenating enzyme from the Malayan pit viper, was withdrawn from some markets and never gained FDA approval. Hemocoagulase formulations vary by manufacturer, which complicates cross-country comparison. The Chinese and Japanese approvals for batroxobin and cobratide are real but narrow.

The deeper limitation is mechanistic. Venom peptides evolved to work within seconds in a predator-prey encounter, so they are tuned for rapid onset and rapid clearance. That makes them excellent acute-care drugs (eptifibatide, tirofiban) and poor chronic-care drugs (captopril required molecular shrinkage to work orally). Future venom-derived medicines will likely follow the same pattern: acute, injectable, narrow-index agents for critical care, with oral chronic drugs requiring substantial reengineering.

The numbers to remember: 7 approved or regionally approved drugs, 1 fully oral (captopril), 2 acute antiplatelet agents, 1 dose-dependent coagulant, 2 neurotoxin-derived analgesics, and 1 investigational scaffold. That is the honest state of the field in November 2026.